BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 21742371)

  • 1. Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40years of age and younger.
    Shih KK; Garg K; Levine DA; Kauff ND; Abu-Rustum NR; Soslow RA; Barakat RR
    Gynecol Oncol; 2011 Oct; 123(1):88-94. PubMed ID: 21742371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
    Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
    Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics.
    Ring KL; Connor EV; Atkins KA; Ricketts W; Kashlan B; Modesitt SC
    Int J Gynecol Cancer; 2013 Jun; 23(5):853-60. PubMed ID: 23552806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables.
    Joehlin-Price AS; Perrino CM; Stephens J; Backes FJ; Goodfellow PJ; Cohn DE; Suarez AA
    Gynecol Oncol; 2014 Apr; 133(1):43-7. PubMed ID: 24444820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lynch syndrome-related endometrial carcinoma].
    Pang SJ; Guo DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):494-7. PubMed ID: 22932468
    [No Abstract]   [Full Text] [Related]  

  • 6. Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type.
    Ruiz I; Martín-Arruti M; Lopez-Lopez E; Garcia-Orad A
    Gynecol Oncol; 2014 Jul; 134(1):20-3. PubMed ID: 24814467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer.
    Backes FJ; Leon ME; Ivanov I; Suarez A; Frankel WL; Hampel H; Fowler JM; Copeland LJ; O'Malley DM; Cohn DE
    Gynecol Oncol; 2009 Sep; 114(3):486-90. PubMed ID: 19515405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of MMR in endometrial adenocarcinoma in women under 50 years old].
    Wu HX; Song JC; Shi YQ; Liu YX
    Zhonghua Bing Li Xue Za Zhi; 2012 Nov; 41(11):733-6. PubMed ID: 23302332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.
    Buchanan DD; Tan YY; Walsh MD; Clendenning M; Metcalf AM; Ferguson K; Arnold ST; Thompson BA; Lose FA; Parsons MT; Walters RJ; Pearson SA; Cummings M; Oehler MK; Blomfield PB; Quinn MA; Kirk JA; Stewart CJ; Obermair A; Young JP; Webb PM; Spurdle AB
    J Clin Oncol; 2014 Jan; 32(2):90-100. PubMed ID: 24323032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
    Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
    Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas.
    Shikama A; Minaguchi T; Matsumoto K; Akiyama-Abe A; Nakamura Y; Michikami H; Nakao S; Sakurai M; Ochi H; Onuki M; Satoh T; Oki A; Yoshikawa H
    Gynecol Oncol; 2016 Feb; 140(2):226-33. PubMed ID: 26644264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved survival with an intact DNA mismatch repair system in endometrial cancer.
    Cohn DE; Frankel WL; Resnick KE; Zanagnolo VL; Copeland LJ; Hampel H; Kelbick N; Morrison CD; Fowler JM
    Obstet Gynecol; 2006 Nov; 108(5):1208-15. PubMed ID: 17077244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
    Chapel DB; Yamada SD; Cowan M; Lastra RR
    Gynecol Oncol; 2018 Jun; 149(3):570-574. PubMed ID: 29656794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers.
    Kato M; Takano M; Miyamoto M; Sasaki N; Goto T; Tsuda H; Furuya K
    J Gynecol Oncol; 2015 Jan; 26(1):40-5. PubMed ID: 25310854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of endometrial cancer abnormal MMR protein in screening Lynch-syndrome families.
    Long Q; Peng Y; Tang Z; Wu C
    Int J Clin Exp Pathol; 2014; 7(10):7297-303. PubMed ID: 25400828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and pathologic features of young endometrial cancer patients with loss of mismatch repair expression.
    Grzankowski KS; Shimizu DM; Kimata C; Black M; Terada KY
    Gynecol Oncol; 2012 Sep; 126(3):408-12. PubMed ID: 22617524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.
    Mills AM; Liou S; Ford JM; Berek JS; Pai RK; Longacre TA
    Am J Surg Pathol; 2014 Nov; 38(11):1501-9. PubMed ID: 25229768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome.
    Nelson GS; Pink A; Lee S; Han G; Morris D; Ogilvie T; Duggan MA; Köbel M
    Gynecol Oncol; 2013 Nov; 131(2):309-14. PubMed ID: 23938375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
    McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
    Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.